Stirling, UK, 13 July 2017-eClinicalHealth introduced Clinpal EDC, an application for data capture on a single cloud platform that enables an intuitive experience for patients and sites as well as all sponsor and CRO stakeholders.
With over five years of development and use in numerous live trials, Clinpal EDC is created for Phase II through Phase IV post-marketing studies, observational studies, and registries, with no upper limit on the number of sites or patients.
“Clinpal EDC offers a modern and advanced cloud approach to electronic data capture that provides natural workflows to sites, sponsors, and CROs, while involving patients in the trial lifecycle,” said Doug Bain, Chief Technology Officer at eClinicalHealth.
Clinpal EDC is a single cloud platform to recruit patients through targeted websites and social networks, qualify and enroll them, and then collect data for retention and protocol compliance throughout the clinical trial process.
“Our EDC platform is unique in that it has shortened delivery times, reduced costs, and enabled sponsors to collect source data directly from thousands of patients while meeting global regulatory requirements,” said Ian Mills, Lead Architect of Clinpal EDC.
The Clinpal EDC package has a patient-centric focus to EDC, is built on a cloud platform, and is suited for commercial, academic, and hospital-based research teams.
To find out more about Clinpal EDC, click here.
About eClinicalHealth
For over 5 years, Clinpal EDC has been capturing data from patients in studies across 41 countries on 6 continents in virtually all local languages. These projects have integrated a variety of biometric data and range from small proof-of-concept trials to large global patient registries.
Contact: Suzie Harvey
Email: info@eClinicalHealth.com
Office: +44 333 012 4205
Web: www.clinpal.com
Join our community: LinkedIn | Twitter
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.